Pain Therapeutics to Present At the UBS Life Sciences Conference


SAN MATEO, Calif., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that management will present at the UBS Global Life Sciences Conference on Tuesday, September 23rd at 4:00 p.m. Eastern Time in New York.

A live audio webcast of the presentation will be open to all on our web site, www.paintrials.com. A replay will also be available three hours after the live event.

About Pain Therapeutics, Inc.

Pain Therapeutics is a biopharmaceutical company that develops novel drugs. In addition to REMOXY(r), the Company has four drug candidates in clinical programs, including PTI-202, PTI-721, Oxytrex(tm) and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Pain Therapeutics is also working on a new treatment for patients with hemophilia. The FDA has not yet evaluated the merits, safety or efficacy of the Company's drug candidates. For more information, please visit www.paintrials.com.



            

Contact Data